University of Crete (UOC)
Αποτελεσματικότητα και ασφάλεια της χρήσης ενδοφλέβιας κολιστίνης σε ασθενείς με λοιμώξεις από πολυανθεκτικά Gram-αρνητικά μικρόβια
Abstract
dc:descriptionColistin, an antibiotic almost abandoned for intravenousadministration for many years, due to its reported toxicity, has beenrecently reintroduced in clinical practice due to the emergence ofmultidrug-resistant Gram-negative bacteria and the lack ofdevelopment of new antibiotics to combat them. However, new dataabout its safety and effectiveness in the treatment of serioushospital-acquired infections in patients without cystic fibrosis arelacking. Thus, the objective of this study was to re-evaluate the useof colistin for the treatment of infections mainly due to strains ofAcinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiellapneumonia.A retrospective cohort study was performed at “Henry Dunant”hospital, a 450-bed tertiary-care hospital. Patients who werehospitalized from 1/October/2000 to 31/January/2004 and receivedintravenous colistin for more than 72 hours were further analyzed.Primary outcome measure was the in-hospital mortality; secondaryend points were the clinical outcome of the infections and theoccurrence of colistin-induced nephrotoxicity.Fifty patients received intravenous colistin with a mean (median)daily dose of 4,5 (3) million IU for 21,3 (16,5) days for themanagement of 54 episodes of infections due to multidrug-resistantGram-negative bacteria. The predominant infections were pneumonia (33,3%), bacteremia (27,8%), urinary tract infection(11,1%), and intra-abdominal infection (11,1%). The responsiblepathogens were Acinetobacter baumannii (51,9%), Pseudomonasaeruginosa (42,6%), and Klebsiella pneumonia (3,7%); nopathogen was isolated from one case. In-hospital mortality was24% (12/50 patients). Clinical response (cure and improvement) ofthe infection was observed in 66,7% of episodes (36/54 episodes ofinfection). In the studied group, serum creatinine levels weredecreased, at the end of colistin treatment, by an average (± SD)of 0,2 (±1,3) mg/dl compared to baseline levels. Deterioration ofrenal function during CMS therapy was observed in 4/50 patients(8%). Multivariable analysis showed that age (OR= 1,059, 95%CI=1,004 – 1,118) and temperature on admission to the hospital (OR=0,383, 95%CI = 0,148 – 0,991) were independent predictors of inhospitalmortality.We further analyzed data for 19 courses of prolonged (more than 4weeks) intravenous colistin administration [mean (±SD) duration ofadministration 43,4 (±14,6) days, mean daily dosage (±SD) 4,4(±2,1) million IU, mean cumulative dosage (±SD) 190,4 (±91)million IU] in 17 patients. The median creatinine value increased by0,25 mg/dl during the treatment compared to the baseline (p<0,001) but returned close to the baseline at the end of treatment(higher by 0,1 mg/dl, p= 0,67). A prospective cohort study was also performed at “Henry Dunant”Hospital to further clarify the issue of colistin inducednephrotoxicity. Patients who received intravenous colistin at least 7days for the treatment of multidrug resistant Gram-negativebacterial infections were included in the study. The development ofnephrotoxicity through evaluations of serum creatinine, blood urea,serum electrolytes, urinalysis, and creatinine and sodium in 24-hoururine collection during intravenous colistin therapy was the primaryend point of the study.Twenty one patients were included in this prospective evaluation.The mean (± SD)/median daily dose of colistin administeredintravenously to the patients was 5,5 (±1,9)/6 million IU and themean (±SD)/median cumulative dose of the medication was 90,2(±52,0)/72 million IU. The range of the duration of intravenouscolistin treatment was 7 - 54 days; the mean (± SD)/medianduration was 17,7 (±11,7)/15 days. Three of the 21 evaluablepatients (14,3%) developed nephrotoxicity during the intravenoustreatment with colistin. The cumulative dose of the administeredcolistin was statistically correlated with the difference betweenbaseline and end of treatment values of serum creatinine (r= 0,6,p= 0,004 by Spearman’s test). No other toxic events were notedduring the intravenous administration of colistin. In conclusion, the use of intravenous colistin for the treatment ofinfections due to multidrug-resistant Gram-negative bacteriaappears to be safe and effective. Colistin should be considered as apossible therapeutic option for these patients.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kasiakou, Sofia
- Κασιάκου, Σοφία
Subjects
dc:subject × 17- Κολιστίνη
- Νεφροτοξικότητα
- Πολυμυξίνες
- Πολυανθεκτικά Gram-αρνητικά μικρόβια
- Νοσοκομειακές λοιμώξεις
- Colistin
- Nephrotoxicity
- Polymyxins
- Multidrug-resistant Gram-negative bacteria
- Hospital acquired infections
- Acinetobacter baumannii
- Pseudomonas aeruginosa
- Klebsiella pneumoniae
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29135